PRAXIS PRECISION MEDICINES, INC. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
PRAXIS PRECISION MEDICINES, INC. (PRAX) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 2.56 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-06
- PRAXIS PRECISION MEDICINES, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-06-30 was 2.56M shares, a 2.66% decline year-over-year.
- PRAXIS PRECISION MEDICINES, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 2.59M shares, a 0.34% increase year-over-year.
- PRAXIS PRECISION MEDICINES, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-09-30 was 2.60M shares, a 26.26% increase year-over-year.
- PRAXIS PRECISION MEDICINES, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-06-30 was 2.63M shares, a 111.87% increase year-over-year.
- PRAXIS PRECISION MEDICINES, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 2.38M shares, a 16.78% increase from fiscal 2024.
- PRAXIS PRECISION MEDICINES, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 2.04M shares, a 176.47% increase from fiscal 2023.
- PRAXIS PRECISION MEDICINES, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 738.28K shares, a 12.30% increase from fiscal 2022.
- PRAXIS PRECISION MEDICINES, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 657.41K shares, a 90.53% decline from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 2.56M shares 10-Q · filed 2026-08-06 | 2.56M shares 10-Q · filed 2026-08-06 | ||||||
| 2026-03-31 | 2.59M shares 10-Q · filed 2026-05-07 | |||||||
| 2025-12-31 | 2.38M shares 10-K · filed 2026-02-19 | |||||||
| 2025-09-30 | 2.60M shares 10-Q · filed 2025-11-05 | 2.60M shares 10-Q · filed 2025-11-05 | ||||||
| 2025-06-30 | 2.63M shares 10-Q · filed 2026-08-06 | 2.63M shares 10-Q · filed 2026-08-06 | ||||||
| 2025-03-31 | 2.58M shares 10-Q · filed 2026-05-07 | |||||||
| 2024-12-31 | 2.04M shares 10-K · filed 2026-02-19 | |||||||
| 2024-09-30 | 2.06M shares 10-Q · filed 2025-11-05 | 2.06M shares 10-Q · filed 2025-11-05 | ||||||
| 2024-06-30 | 1.24M shares 10-Q · filed 2025-08-04 | 1.24M shares 10-Q · filed 2025-08-04 | ||||||
| 2024-03-31 | 1.21M shares 10-Q · filed 2025-05-02 | |||||||
| 2023-12-31 | 738.28K shares 10-K · filed 2026-02-19 | |||||||
| 2023-09-30 | 711.44K shares 10-Q · filed 2024-11-06 | 10.67M shares 10-Q · filed 2023-11-07 | 711.44K shares 10-Q · filed 2024-11-06 | 10.67M shares 10-Q · filed 2023-11-07 | ||||
| 2023-06-30 | 728.86K shares 10-Q · filed 2024-08-13 | 10.93M shares 10-Q · filed 2023-08-09 | 728.86K shares 10-Q · filed 2024-08-13 | 10.93M shares 10-Q · filed 2023-08-09 | ||||
| 2023-03-31 | 775.04K shares 10-Q · filed 2024-05-13 | 11.63M shares 10-Q · filed 2023-05-11 | ||||||
| 2022-12-31 | 657.41K shares 10-K · filed 2024-03-05 | 9.87M shares 10-K · filed 2023-02-07 | ||||||
| 2022-09-30 | 10.00M shares 10-Q · filed 2023-11-07 | 10.00M shares 10-Q · filed 2023-11-07 | ||||||
| 2022-06-30 | 10.74M shares 10-Q · filed 2023-08-09 | 10.74M shares 10-Q · filed 2023-08-09 | ||||||
| 2022-03-31 | 8.73M shares 10-Q · filed 2023-05-11 | |||||||
| 2021-12-31 | 6.94M shares 10-K · filed 2023-02-07 | |||||||
| 2021-09-30 | 6.80M shares 10-Q · filed 2022-11-09 | 6.80M shares 10-Q · filed 2022-11-09 | ||||||
| 2021-06-30 | 6.95M shares 10-Q · filed 2022-08-08 | 6.95M shares 10-Q · filed 2022-08-08 | ||||||
| 2021-03-31 | 6.98M shares 10-Q · filed 2022-05-09 | |||||||
| 2020-12-31 | 5.94M shares 10-K · filed 2022-02-28 | |||||||
| 2020-09-30 | 30.89M shares 10-Q · filed 2021-11-03 | 30.89M shares 10-Q · filed 2021-11-03 | ||||||
| 2020-06-30 | 19.22M shares 10-Q · filed 2021-08-16 | 19.22M shares 10-Q · filed 2021-08-16 | ||||||
| 2020-03-31 | 15.52M shares 10-Q · filed 2021-05-11 | |||||||
| 2019-12-31 | 18.25B shares 10-K · filed 2021-03-17 | |||||||
| 2019-09-30 | 13.71M shares 10-Q · filed 2020-11-23 | 13.71M shares 10-Q · filed 2020-11-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |